Výsledky vyhledávání - "Ashleigh Herriott"

Supplementary Figure S1 from Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

Autor: Zev A. Wainberg, Lauren Averett Byers, Nicola J. Curtin, Miranda Patterson, Ashleigh Herriott, Joshua W. Henshaw, David C. Smith, John Heymach, Jasgit Sachdev, Stan Kaye, Saeed Rafii, John Glaspy, Rashmi Chugh, Lida Mina, Ramesh K. Ramanathan, Johann de Bono

Supplementary Figure S1. Talazoparib inhibition of PBMC PARP activity.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36e95db2be5b81e9a0f3ad86b8281bd1
https://doi.org/10.1158/2159-8290.22531110

Zobrazit plný text záznamu

Supplementary Methods from Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

Supplementary Methods includes additional details on these topics: tumors eligible for dose escalation phase; tumors eligible for dose expansion phase; patients enrolled using a local laboratory; study design and participants; additional inclusion cr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c35bb32f493e71bbc643b22bb0b3649
https://doi.org/10.1158/2159-8290.22531107.v1

Zobrazit plný text záznamu

Supplementary Table S1 from Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

Supplementary Table S1. Dose-response and exposure-response parameters.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b99fccdd412f6f65d1dfdcba0f9d8d0
https://doi.org/10.1158/2159-8290.22531104

Zobrazit plný text záznamu

Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types

Autor: Lucy Gentles, Nicola J. Curtin, Asima Mukhopadhyay, Sally Hall, Angelika Kaufmann, Yvette Drew, Rachel O'Donnell, Bojidar Goranov, Elizabeth Matheson, Ashleigh Herriott

Publikováno v: Cancers, Vol 11, Iss 3, p 354 (2019)
Cancers
Volume 11
Issue 3

Dysfunctional homologous recombination DNA repair (HRR), frequently due to BRCA mutations, is a determinant of sensitivity to platinum chemotherapy and poly(ADP-ribose) polymerase inhibitors (PARPi). In cultures of ovarian cancer cells, we have previ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1481f51f85f5eda79886be4d452c6f80
https://doi.org/10.3390/cancers11030354

Zobrazit plný text záznamu

Plný text ve formátu HTML

Kinetochore localized Mad2 and Cdc20 is itself insufficient for triggering the mitotic checkpoint when Mps1 is low in Drosophila melanogaster neuroblasts

Autor: Michael J. Taggart, Ashleigh Herriott, M Sweeney, Jun-Yong Huang, Michael Whitaker

Publikováno v: Cell Cycle

The relationships between the kinetochore and checkpoint control remain unresolved. Here, we report the characterization of the in vivo behavior of Cdc20 and Mad2 and the relevant spindle assembly checkpoint (SAC) functions in the neuroblasts of a Dr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c78ae5ffc6dacb0a449bd7728b759a0b
http://europepmc.org/articles/PMC3562310

Zobrazit plný text záznamu

Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition

Autor: Aiste McCormick, Nicola J. Curtin, Sarah E. Fordham, Claire Elstob, Felicity E. B. May, Miranda J. Patterson, Mark Wade, Ashleigh Herriott, Fiona K. Middleton, John Pollard, James M. Allan, Richard J. Edmondson

Publikováno v: Oncotarget

ATR is an attractive target in cancer therapy because it signals replication stress and DNA lesions for repair and to S/G2 checkpoints. Cancer-specific defects in the DNA damage response (DDR) may render cancer cells vulnerable to ATR inhibition alon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce6454c73a1d8079256b2ac150725caf
https://pubmed.ncbi.nlm.nih.gov/26486089

Zobrazit plný text záznamu

Abstract A220: Inhibition of PBMC PARP activity with the novel PARP 1/2 inhibitor BMN 673 in patients with advanced solid tumors

Autor: Andrew Dorr, Johann S. de Bono, Huiyu Zhou, Nicola J. Curtin, Lida Mina, Joshua Henshaw, Evelyn Wang, Ashleigh Herriott, Don Musson, Ramesh K. Ramanathan, Charles A. O'Neill, Miranda J. Patterson

Publikováno v: Molecular Cancer Therapeutics. 12:A220-A220

Introduction: BMN 673 is a novel, potent (IC50 < 1.0 nM) inhibitor of Poly(ADP-ribose) polymerase (PARP) 1 and PARP 2 in clinical development for the treatment of genetically defined cancers. Methods: The pharmacokinetics (PK) and pharmacodynamics (P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f18970d916240e225ca5f1008a3fc823
https://doi.org/10.1158/1535-7163.targ-13-a220

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání